Table 1 Fitted mean of sample size and 95% confidence interval back transformed from logarithmic values, type III F statistic and the corresponding p value of the effect of class of prevalence on sample size adjusting for phase and interaction between prevalence and phase, and without adjustment for other covariates and with adjustment for other covariatesa
Characteristics | Without adjustment for other covariates | With adjustment for other covariates | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
No. of trials, m | Fitted mean | 95% CI | F test | p value | No. of trials, m | Fitted mean | 95% CI | F test | p value | ||
Prevalence class | 17.38 | <.0001 | 20.73 | <.0001 | |||||||
<1/1,000,000 | 19 | 21.21 | (11.63–38.67) | 18 | 28.61 | (14.43–56.73) | |||||
1–9/1,000,000 | 88 | 40.57 | (32.18–51.14) | 66 | 55.23 | (33.76–90.37) | |||||
1–9/100,000 | 587 | 74.19 | (67.71–81.29) | 483 | 90.09 | (58.66–138.36) | |||||
1–5/10,000 | 454 | 86.37 | (78.32–95.25) | 359 | 93.10 | (60.58–143.08) | |||||
Phase of investigation b | 21.56 | <.0001 | 324.97 | <.0001 | |||||||
Phase 2 | 841 | 32.84 | (28.61–37.69) | 677 | 46.34 | (29.86–71.90) | |||||
Phase 3 | 307 | 71.50 | (53.05–96.38) | 249 | 78.57 | (47.48–130.02) | |||||
Prevalence × Phase | 6.40 | 0.0003 | 2.75 | 0.0415 | |||||||
Phase 2 | <1/1,000,000 | 16 | 18.05 | (11.20–29.09) | 15 | 26.96 | (14.74–49.31) | ||||
1–9/1,000,000 | 65 | 35.23 | (27.80–44.65) | 48 | 49.04 | (29.87–80.51) | |||||
1–9/100,000 | 442 | 41.52 | (37.92–45.47) | 365 | 58.70 | (38.14–90.32) | |||||
1–5/10,000 | 318 | 44.04 | (39.57–49.02) | 249 | 59.42 | (38.62–91.43) | |||||
Phase 3 | <1/1,000,000 | 3 | 24.92 | (8.28–75.06) | 3 | 30.37 | (10.37–88.92) | ||||
1–9/1,000,000 | 23 | 46.71 | (31.37–69.56) | 18 | 62.21 | (34.40–112.49) | |||||
1–9/100,000 | 145 | 132.56 | (113.12–155.35) | 118 | 138.28 | (88.39–216.34) | |||||
1–5/10,000 | 136 | 169.39 | (143.80–199.53) | 110 | 145.86 | (92.79–229.30) | |||||